OpenMTA certainly recovers the costs associated with the production and distribution of materials and could therefore also be used for the transfer of research reagents such as antibodies, cell lines and fluorescent proteins for which patents have expired or have never been sought. Indeed, the introduction of OpenMTA for the sharing of biological materials is particularly current, since many patented materials are now made public due to the expiry of patents. For example, a collection of patents on green fluorescent proteins, initially aggregated and over-licensed by GEcare Lifesciences16, have all expired (Table 2). In addition, claims on nucleic acid sequences are now subject to enhanced review and, if granted, much tighter than in the past17,18. We have received numerous requests regarding OpenMTA`s ability to transfer human material. Additional complexities such as data protection, consent and consent between institutional review and verification boards need to be addressed, and we are working with others to develop an OpenMTA for these materials. Expanding these efforts towards more open sharing of induced pluripotent stem cell lines, for example in coordination with national and international registries, could significantly accelerate the development of useful biomedical applications. The differences between OpenMTA and other standard models are due to design differences, particularly the fact that researchers can use the materials for legitimate purposes, including for commercial purposes, and that materials can be redistributed to others, provided they are reported at the request of the provisioning institution. The reports were included as an optional term, as technology transfer agencies expressed different preferences. Some wanted the cover to be a means of measuring the influence of the research material, which was made free to others, while others did not want to follow the materials beyond the first transfer. This article is licensed Creative Commons Attribution 4.0 International License, which allows use, release, customization, distribution and reproduction in any medium or format, provided you give the original author and source a link to the Creative Commons license and if you specify if any changes have been made. The images or other third-party material contained in this article are included in the article`s Creative Commons license, unless otherwise stated in a hardware credit. If the material is not included in the Creative Commons license of the article and your intention to use it is not authorized by law or if the authorized use exceeds, you must obtain permission directly from the copyright holder.

To view a copy of this license, visit creativecommons.org/licenses/by/4.0/ A Material Transfer Agreement (MTA) is a legal contract to document the transfer of physical material between Yale University and academic, non-profit or industrial institutions. MTAs are mainly used to document the transfer of biological materials (plasmids, cell lines, mouse strains, etc.), but can also be used for the transmission of certain types of non-biological materials. Each member of Yale`s faculty must ensure that an MTA is present before receiving or sending the material. It is important to note that the signing of the OpenMTA master`s contract offers an institution and its researchers the opportunity to transfer materials in accordance with the terms of openMTA, but that their exclusive use is not mandatory. Institutions retain the flexibility to process the transfer of certain materials on a bespoke basis.